ArticleBMC cancer2025
CLIC3 emerges as a novel prognostic biomarker and therapeutic target in triple-negative breast cancer through integrated multi-omics analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell analysis reveals an endothelial TP53-CXCL14 axis in breast cancer progression.Journal of translational medicine · 2026Article
- A pooled CRISPR screen reveals genes critical for erythroblast enucleation.bioRxiv : the preprint server for biology · 2026Article
- CLIC3 is upregulated across all subtypes of breast cancer and plays a key role in cell migration, invasion and growth in soft agar.Breast cancer research : BCR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) remains clinically challenging due to its aggressiveness, limited targeted therapies, and absence of reliable prognostic biomarkers. Identifying TNBC-specific molecular drivers is critical for improving patient outcomes.
methodsWe employed an integrated multi-omics approach to analyze tumor and adjacent normal tissues from 4 TNBC and 4 non-TNBC patients via RNA sequencing (RNA-seq) and whole-exome sequencing (WES), complemented by an extensive analysis of 115 TNBC and 976 non-TNBC samples from The Cancer Genome Atlas (TCGA). Prognostic screening was performed to identify potential biomarkers correlated with patient survival. In vitro experimental validation was carried out in MDA-MB-231 TNBC cells, and immunohistochemistry was used to confirm protein expression levels.
resultsWeighted Gene Co-expression Network Analysis (WGCNA) and comparative WES analysis revealed that TNBC exhibited unique transcriptional modules enriched in DNA replication and heterochromatin organization, distinct somatic mutation landscapes, and alternative splicing patterns. Prognostic screening identified chloride intracellular channel 3 (CLIC3) as the top risk factor for poor survival. In vitro experimental validation showed that CLIC3 knockdown significantly inhibited proliferation (CCK-8, colony formation , invasion and migration in MDA-MB-231 TNBC cells. Immunohistochemistry assay confirmed significantly higher CLIC3 protein expression in TNBC versus non-TNBC tissues.
conclusionsCLIC3 is a TNBC-specific prognostic biomarker and therapeutic target. Its inhibition impedes TNBC aggressiveness, providing a foundation for targeted therapy development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.